Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

PNA Letter - Intersol

Our STN: BN 080041/0

Fenwal, Inc.
Attention: Mr. Matthew Nowland
Three Corporate Drive
Lake Zurich, IL 60047

Dear Mr. Nowland:

We have reviewed your submission dated June 5, 2009, to your new drug application (NDA) for InterSol Solution requesting a proprietary name review.

In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, InterSol Solution, is acceptable at this time.

We will perform another proprietary name review of InterSol Solution closer to the time of the action due date to ensure that we have not approved a conflicting proprietary name for another product in the interim.

If you have any questions, please contact the Regulatory Project Manager, Heather Erdman, at (301) 827-6182.

Sincerely yours,


Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
Evaluation and Research


Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.